WINCHESTER, Mass., Jan. 19, 2016 /PRNewswire/ -- Applied BioMath, LLC (www.appliedbiomath.com) today announced a collaboration with Zymeworks Inc. (www.zymeworks.com), a leader in the development of bi-specific antibodies, to leverage Applied BioMath's proprietary analytical and predictive capabilities in quantitative systems pharmacology.
Under the terms of the agreement, Applied BioMath will assist Zymeworks on multiple programs focusing on bi-specific antibody drug conjugate therapeutics for oncology. Applied BioMath's industry leading analytics and toolsets will enable both:
GLP toxicology studies, such as dose selection, design, time point collection, and interpretation of results, and
First-in-human dose predictions for IND filings
"We are very excited to be working with such an industry leader as Zymeworks who is pioneering new approaches to antibody drug conjugates that promise to revolutionize treatments in oncology," said Dr. John Burke, PhD. "Our rigorous approach to in silico modeling, which focuses on the biology, will provide Zymeworks with insight into disease pathomechanisms and pharmacology. This insight will aid in the prediction of safe dose ranges in humans and therapeutic doses in patients, increasing the likelihood of clinical success."